Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02867605
Other study ID # 16-142
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date June 20, 2019

Study information

Verified date August 2020
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether oral HA35 supplementation changes the normal intestinal bacteria, increases intestinal protection, decrease intestinal inflammation and permeability, and to assess any health benefits and confirm the safety profile of HA35.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 20, 2019
Est. primary completion date September 20, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- BMI 19-25 (lean), and BMI 30-35 (obese)

- Age 18-45 years old

- Willingness to take oral supplement and adhere to study requirements

Exclusion Criteria:

- Diabetes

- Oral antibiotics within 4 weeks of study initiation

- History of cardiac disease, and medications for cardiac disease

- Use statins and antihypertensive drugs

- Inflammatory bowel disease including irritable bowel syndrome

- History of intestinal surgery, excluding hernia repair and appendectomy

- Active cancer diagnosis (except skin cancer)

- Chronic acid suppression treatment (proton pump inhibitors, histamine H2 receptor antagonists)

- Immune modulatory treatments (e.g. chronic immunosuppressive medications, chronic NSAIDs)

- Vegetarian or vegan diet7

- Abnormal liver or kidney function as measured by routine serum chemistry testing

- Severe anemia or significant white blood cell or platelet abnormalities

- No additional blood or blood product donations during the study

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Hyaluronan


Locations

Country Name City State
United States Cleveland Clinic Foundation Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

References & Publications (2)

Hill DR, Kessler SP, Rho HK, Cowman MK, de la Motte CA. Specific-sized hyaluronan fragments promote expression of human ß-defensin 2 in intestinal epithelium. J Biol Chem. 2012 Aug 31;287(36):30610-24. doi: 10.1074/jbc.M112.356238. Epub 2012 Jul 3. — View Citation

Hill DR, Rho HK, Kessler SP, Amin R, Homer CR, McDonald C, Cowman MK, de la Motte CA. Human milk hyaluronan enhances innate defense of the intestinal epithelium. J Biol Chem. 2013 Oct 4;288(40):29090-104. doi: 10.1074/jbc.M113.468629. Epub 2013 Aug 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Composition of Stool Micro Biome Diversity and Phylogenetic Distribution at 0 Days, 8 Days and 28 Days Relative abundance is defined as the proportion of total identified bacteria in a sample that are a given type of bacteria. As an example a relative abundance of firmicutes equal to 0.9 would mean that 90% of the bacteria identified in a sample are firmicutes Baseline, Day 8, Day 28
Primary Laboratory Parameters at Day 0, Day 8 and 28 Calcium, Bilirubin, Glucose, Blood Urea Nitrogen, Creatinine Baseline, Day 8, Day 28
Primary Indirect Calorimetry Data at 0 Day, 8 Days and 28 Days Volume of Oxygen and Volume Carbon Dioxide Baseline, Day 8, Day 28
Primary Indirect Calorimetry Data at 0 Day, 8 Days and 28 Days Respiratory Quotient RQ The respiratory quotient is a ratio between the volume of carbon dioxide exhaled and the volume of oxygen inhaled during respiration. It typically ranges between 0.7 and 1.0 and is an indicator of metabolic fuel or substrate use in tissues; it must be calculated under resting or steady-state exercise conditions. A ratio of 0.7 is indicative of mixed fat use, whereas a ratio of 1.0 indicates the exclusive use of carbohydrates Baseline, Day 8, Day 28
Primary Fecal Intestinal Antimicrobial Peptide Secretion at 0 Days, 8 Days and 28 Days Total Protein Baseline, Day 8, Day 28
Primary Fecal Intestinal Antimicrobial Peptide Secretion at 0 Days, 8 Days and 28 Days Normalized Calprotectin and Human Beta-Defensin2 Baseline, Day 8, Day 28
Primary Serum Indicators of Intestinal Permeability at 0 Days, 8 Days and 28 Days Serum Lipopolysaccharide, Hyaluronan Baseline, Day 8, Day 28
Primary Serum Indicators of Inflammation and Injury at Baseline, 8 Days and 28 Days-tumor Necrosis Factor (TNF) Alpha, Interleukin 6 (IL-6) Baseline, Day 8, Day 28
Primary Baseline Serum Indicators of Inflammation and Injury at Baseline, 8 Days and 28 Days-C-reactive Protein Baseline, Day 8, Day 28
Primary Blood Protein, Hemoglobin and Albumin Levels at Baseline, Day 8, and Day 28 Baseline, day 8 day 28
Primary White Blood Cell and Platelet Count at Baseline, Day 8, and Day 28 baseline, day 8, and day 28
Primary Alkaline Phosphatase, Alanine Transaminase , and Aspartate Transaminase at Baseline, Day 8, and Day 28 baseline, day 8, and day 28
Primary Serum Sodium, Potassium, and Carbon Dioxide at Baseline Day 8 and Day 28 baseline, day 8, and day 28
Primary Resting Energy Expenditure (REE) and Metabolic Rate at Baseline Day 8 an Day 28 Baseline, day 8, and day 28
Primary Resting Energy Expenditure as a Percent of Predicted at Baseline, Day 8, and Day 28 This values measures the amount of energy a person uses during rest and compares it the average expected number of someone who is the same gender, age, and race. Baseline, day 8, and day 28
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05371704 - The Effect of Micronutrient Supplementation on Gut Microbiome Composition and Function N/A
Recruiting NCT05961189 - Influence of Short-Term Antibiotic Therapy on Exercise Early Phase 1
Not yet recruiting NCT06126094 - Benefits of Alcoholic Hangover Medicine N/A
Completed NCT06087146 - Modulation of the Gut Microbiota of Professional Athletes With Sauerkraut Supplementation N/A
Not yet recruiting NCT05364736 - Effect of Prebiotics on Blood Pressure Management N/A
Completed NCT03949543 - The Timing of Main Meal Consumption Effect on Gut Microbiota and Host N/A
Recruiting NCT05636670 - Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
Completed NCT02998177 - Characterization of Rebound Pain Following Peripheral Nerve Block and Its Association With Gut Microbiome Diversity N/A
Recruiting NCT05657730 - Study the Effect of Water Kefir Consumption on the Gut Microbiome in Healthy Adults N/A
Active, not recruiting NCT03978104 - Impact of Okara and Bio-okara Food Product on Gut and Glycaemic Health in Middle-aged and Older Adults in Singapore N/A
Terminated NCT04059666 - Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas N/A
Completed NCT04088474 - Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora N/A
Not yet recruiting NCT06332898 - The Effects of a Nutritional Supplement on Nutrient Status and Quality of Life N/A
Completed NCT04046432 - Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity N/A
Completed NCT05729269 - Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass
Recruiting NCT05692024 - COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER Phase 1/Phase 2
Not yet recruiting NCT06207136 - Microbiome and Diet in Parkinson's Disease N/A
Recruiting NCT03812445 - Cognition and Gut Microbiome Associated Study of Shanghai People With Acute Ischemic Stroke N/A
Not yet recruiting NCT04947930 - Fecal Metagenomics and Metabolomics Analyses to Identify Potential Screening Biomarkers for Colorectal Polyps and Cancer in Chinese Population
Recruiting NCT04031469 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease